Instructions for Triazavirin (riamilovir)
English Product Name
Triazavirin
Release Form Triazavirin
caps. 250 mg: 10 or 20 pcs.
Description
The capsules are solid gelatin No. 1, the body is yellow and the lid is red; the capsules contain microcrystalline powder or granules of yellow or yellow-green color.
1 caps.
triazavirin 250 mg
Auxiliary substances: calcium stearate - 2 mg.
The composition of the capsule body: titanium dioxide, quinoline yellow dye, sunset yellow dye, medical gelatin.
The composition of the capsule lid: titanium dioxide, dye azorubin, gelatin medical.
ATX codes
J05AX Other antiviral drugs
Clinical and pharmacological groups / Group affiliation
Antiviral drug
Active ingredient
triazavirin
Pharmacotherapeutic group Triazavirin
Antiviral agent
Retention conditions riamilovir
The drug should be stored in areas that children cannot reach.
Expiration date
The expiration date is two years.
"Pharmacological action and application
Triazavirin exhibits a powerful antiviral effect, being a synthetic analog of guanine, the base of purine nucleosides. Its impact on viruses of PHK-containing species is comprehensive and extensive.
Basic principles of action
One of the main mechanisms of Triazavirin's action is its ability to suppress viral RNA synthesis and genomic replication.
Indications for application
This drug is highly effective in treating influenza in adults. If necessary, it can be combined with the use of symptomatic means to improve the result.
Method of use, dosage and course of treatment riamilovir
Triazavirin must be taken by mouth regardless of food intake.
Recommended Dosage
Begin taking the drug no later than the second day of illness (when the first clinical symptoms appear). It is recommended to take 1 capsule (250 mg) of Triazavirin three times a day (total daily dose is 750 mg) for 5 days. If necessary, treatment can be extended up to 7 days."
- Nosology Triazavirin (ICD codes)
- J10
- Influenza due to identified seasonal influenza virus
- J11
- Influenza, unspecified